


I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office on the date shown below:

February 14, 2008

Margaret Efron, Patent Attorney

STATEMENT OF SUBSTANCE OF
INTERVIEW

Examining Group 1617
Patent Application
Docket No. UF-368XC1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Shengjun Wang
Art Unit : 117
Applicants : Nathan Andrew Shapira *et al.*
Serial No. : 10/809,631
Filed : March 24, 2004
Confirm. No. : 8943
For : Methods for Treating Idiopathic Hyperhidrosis and Associated Conditions

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF SUBSTANCE OF INTERVIEW

The undersigned and Examiner Shengjun Wang conducted a telephonic interview on September 17, 2007.

The interview was conducted with regard to the applicants' election filed July 11, 2007; the applicants were notified that the election of species was not considered fully responsive by Examiner Wang. During the interview, the applicants further elected mirtazapine as the single disclosed species

without traverse. The statement of substance of the interview of September 17, 2007, including the applicants further election of mirtazapine, was summarized in their Response dated January 9, 2008. The subject Statement is being furnished to supplement the statement supplied in the Response.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Margaret Efron
Patent Attorney
Registration No. 47,545
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
P.O. Box 142950
Gainesville, FL 32614-2950

MHE/la